

## Programme

### 4<sup>th</sup> Cancer Crosslinks 2012

January 12<sup>th</sup>, 2012 – Auditorium, New Research Building at the Radiumhospital

8:30 - 9:30	<b>REGISTRATION &amp; COFFEE</b>
9:30 - 9:45	Cancer Crosslinks: Welcome, objectives and organizers <i>Jónas Einarsson, Chairman of the Board, Oslo Cancer Cluster</i>
<b>SESSION 1: Theory meets reality: has the era of personalized medicine come to Norway?</b>	
<b>Are we prepared?</b>	
<i>Chair: Per Eystein Lønning, Haukeland University Hospital Bergen</i>	
9:45 - 10:00	Introduction of topic and speakers by <i>Per Eystein Lønning</i>
10:00 - 10:30	Opening Keynote Stratified medicines programme: Tumour profiling and data capture to improve cancer care <i>James Peach, Director Stratified Medicine at Cancer Research UK, London</i>
10:30 - 10:55	Programme for optimized treatment of Norwegian Cancer Patients - Status, challenges and opportunities for Norway <i>Ola Myklebost, Institute for Cancer Research, Oslo University Hospital</i>
10:55 - 11:10	Drug discovery in the era of personalized medicine: selection of tumour types and target patients – novel approaches and future trends <i>Anna Edsfors Åleskog, MSD</i>
11:10 - 11:20	Wrap-Up
11:20 - 11:50	<b>COFFEE &amp; NETWORKING BREAK</b>
<b>SESSION 2: How does personalized medicine affect drug development and treatment?</b>	
<b>Perspectives from Norwegian Tumour Groups</b>	
<i>Chairs: Jan Oldenburg (Oncologist) and Yngvar Fløisand (Haematologist), both: Oslo University Hospital</i>	
11:50 - 12:00	Introduction of topic and speakers by <i>Jan Oldenburg and Yngvar Fløisand</i>
12:00 - 12:20	<b>CML Group:</b> Collaboration on a Nordic and European level <i>Henrik Hjorth-Hansen, St. Olavs Hospital Trondheim</i>
12:20 - 13:05	<b>Lymphoma Group</b> – research and clinical perspective <i>Bjørn Østenstad, Oslo University Hospital and Erlend Smeland, Institute for Cancer Research OUS</i>
13:05 - 14:00	<b>LUNCH &amp; NETWORKING BREAK</b>
14:00 - 14:55	<b>Melanoma Group</b> – research and clinical perspective <i>Gunhild Mælandsmo and Gustav Gaudernack, Institute for Cancer Research, OUS Marta Nyakas, Oslo University Hospital</i>
14:55 - 16:00	<b>Breast Cancer and Gynaecological Cancer Group:</b> Heterogeneity of breast cancer; a challenge for successful treatment <i>Anne-Lise Børresen-Dale, Institute for Cancer Research, Oslo University Hospital</i> Clinical perspectives: <i>Erik Wist, Oslo University Hospital for the Breast Cancer Group Gunnar Kristensen, Oslo University Hospital for the Gynaecological Cancer Group</i>
16:00 - 16:05	Wrap-up
16:05 - 16:30	<b>COFFEE &amp; NETWORKING BREAK</b>
<b>SESSION 3: New drugs for Norwegian Patients – current climate for the approval of innovative drugs</b>	
<i>Chairs: Steinar Aamdal, Oslo University Hospital and Nils Wilking, Karolinska Institute Stockholm and Division of Oncology and Haematology, SUS Lund</i>	
16:30 - 16:50	Introduction – a clinicians perspective <i>Steinar Aamdal, Oslo University Hospital</i>
16:50 - 17:05	<i>Scientific collaboration between industry, clinicians and patients in drug development</i> <i>Benedikte Thunes-Akre, Bristol-Myers Squibb</i>
17:05 - 17:30	How does the Norwegian Medicines Agency evaluate new cancer drugs? <i>Torunn Wangen, Head of the oncology assessors team, Norwegian Medicines Agency</i>
17:30 - 17:50	International perspectives: funding innovative treatments and market uptake <i>Nils Wilking, Karolinska Institute Stockholm &amp; Division of Oncology and Haematology, SUS Lund</i>
17:50 - 18:00	Q & A and Wrap-up
18:00 - 21:00	<b>NETWORKING EVENING WITH TAPAS &amp; WINE</b>